Precipio Earnings Call Transcripts
Fiscal Year 2026
-
Record Q2 revenue exceeded $7 million, with strong year-over-year and sequential growth. Adjusted EBITDA turned positive, and $700,000 in operating cash was generated, all without external financing. Product division growth and expanded commercial pipeline position the business for continued momentum.
-
Profitability was achieved in Q3 2025, driven by a unique, rapid diagnostic platform and a shift toward high-margin products. The company targets significant market share in blood cancers, leveraging distributor partnerships and a scalable business model, with no customer attrition to date.
-
Shareholders approved the re-election of three directors for three-year terms and ratified the appointment of the independent auditor for 2026. All proposals passed, with results to be filed with the SEC.
-
Q1 2026 revenue was flat sequentially but up 30% year-over-year, with pathology growth offset by product shipment timing and an 8% CMS reimbursement cut. Commercial pipeline expanded to $10M, and margins are expected to recover as investments yield results.
Fiscal Year 2025
-
Achieved positive cash flow and 30% revenue growth in 2025, driven by Pathology Services and improved margins. Products Division poised for growth in 2026 with new commercial hires and scalable manufacturing, targeting a $500M addressable market.
-
Q3 2025 saw record revenue, first-ever positive adjusted EBITDA, and strong cash generation, driven by double-digit growth in both divisions and margin expansion. Strategic investments set the stage for continued growth and financial independence.
-
Q2 2025 delivered strong revenue growth, improved margins, and progress toward break-even, with Pathology Services and Products Divisions both performing well. Strategic investments and a warrant conversion minimized dilution, while a robust customer pipeline supports continued momentum.
-
Q1 2025 saw 43% year-over-year revenue growth, margin expansion, and improved cash use, despite seasonal headwinds. Regulatory wins and the resolution of FDA LDT uncertainty are expected to drive further growth, with positive cash flow anticipated by Q2 or Q3.
Fiscal Year 2024
-
Q4 2024 saw nearly 26% revenue growth year-over-year, positive adjusted EBITDA, and positive cash flow, with the pathology division exceeding break-even and the product division maintaining a $700K run rate. Strategic focus for 2025 includes scaling growth and enhancing market visibility.
-
Q3 2024 results show strong growth, with pathology revenues up 18% and products up 13% sequentially. Cash burn dropped 75% year-over-year, and break-even is within reach, eliminating the need for further capital raises.
-
Revenue grew to $4.4M in Q2 2024, with the pathology division exceeding breakeven and the products division nearing profitability. Cash position improved, and FDA approval is targeted for 2025, expected to boost market share and valuation.